133 related articles for article (PubMed ID: 17497733)
21. Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate.
Samy R; Faustino PJ; Adams W; Yu L; Khan MA; Yang Y
J Pharm Biomed Anal; 2010 Apr; 51(5):1108-12. PubMed ID: 20031362
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate.
Yang Y; Mohammad A; Berendt RT; Carlin A; Khan MA; Faustino PJ
J Pharm Sci; 2016 Feb; 105(2):864-875. PubMed ID: 26219932
[TBL] [Abstract][Full Text] [Related]
23. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
Yaguchi A; Akahane K; Tsuchioka K; Yonekubo S; Yamamoto S; Tamai Y; Tatemichi S; Takeda H
BMC Nephrol; 2019 Dec; 20(1):465. PubMed ID: 31830936
[TBL] [Abstract][Full Text] [Related]
24. Transient acid exposure increases sevelamer HCl phosphate binding.
Ross EA; Scott WE; Odukale AA; Alba NA; Batich CD
J Pharm Sci; 2007 Aug; 96(8):2154-60. PubMed ID: 17506513
[TBL] [Abstract][Full Text] [Related]
25. [Phosphate binder up to date].
Shigematsu T; Sakaguchi T; Orita H
Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
[TBL] [Abstract][Full Text] [Related]
26. Sevelamer carbonate.
Barna MM; Kapoian T; O'Mara NB
Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
[TBL] [Abstract][Full Text] [Related]
27. Effects of efficient phosphate binding on bone in chronic renal failure rats.
Behets GJ; Gritters M; Dams G; De Broe ME; D'Haese PC
Ren Fail; 2005; 27(4):475-84. PubMed ID: 16060138
[TBL] [Abstract][Full Text] [Related]
28. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
Pai AB; Shepler BM
Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
[TBL] [Abstract][Full Text] [Related]
29. Kinetic and thermodynamic evaluation of phosphate ions binding onto sevelamer hydrochloride.
Elsiddig R; Hughes H; Owens E; O' Reilly NJ; O'Grady D; McLoughlin P
Int J Pharm; 2014 Oct; 474(1-2):25-32. PubMed ID: 25102115
[TBL] [Abstract][Full Text] [Related]
30. Effect of fatty acids on the phosphate binding of TRK-390, a novel, highly selective phosphate-binding polymer.
Nakaki J; Yamaguchi S; Torii Y; Inoue A; Minakami S; Kanno T; Murakami M; Tsuzuki M; Mochizuki H; Suyama K; Miyamoto M
Eur J Pharmacol; 2013 Aug; 714(1-3):312-7. PubMed ID: 23911881
[TBL] [Abstract][Full Text] [Related]
31. High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders.
Sprague SM; Reddy G; Jermasek D; Gupta P
Am J Nephrol; 2023; 54(5-6):219-223. PubMed ID: 37231835
[TBL] [Abstract][Full Text] [Related]
32. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
Taniguchi K; Kakuta H
Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
[TBL] [Abstract][Full Text] [Related]
33. The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties.
Elsiddig R; O'Reilly NJ; Hudson SP; Owens E; Hughes H; O'Grady D; McLoughlin P
Int J Pharm; 2022 Jun; 621():121806. PubMed ID: 35526696
[TBL] [Abstract][Full Text] [Related]
34. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
Rosenbaum DP; Holmes-Farley SR; Mandeville WH; Pitruzzello M; Goldberg DI
Nephrol Dial Transplant; 1997 May; 12(5):961-4. PubMed ID: 9175050
[TBL] [Abstract][Full Text] [Related]
35. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
[TBL] [Abstract][Full Text] [Related]
36. Endotoxin-binding affinity of sevelamer hydrochloride.
Perianayagam MC; Jaber BL
Am J Nephrol; 2008; 28(5):802-7. PubMed ID: 18506105
[TBL] [Abstract][Full Text] [Related]
37. Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.
Sanai T; Tada H; Ono T; Fukumitsu T
Hemodial Int; 2015 Jan; 19(1):54-9. PubMed ID: 24980286
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
39. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
Burke SK; Slatopolsky EA; Goldberg DI
Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
[TBL] [Abstract][Full Text] [Related]
40. Lanthanum carbonate as a first-line phosphate binder: the "cons".
Drüeke TB
Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
